European Vaccine Hub to enhance health preparedness across EU
The initiative consist of key actions, that will amongst others, speed-up vaccine development to less than four months from identifying a pathogen's genomic sequence.
News
Policy & Recommendations
Promoting vaccination amongst the elderly with VITAL’s new tools
The VITAL project published an educational platform as well as a toolbox to boost vaccination uptake amongst older people.
Next-generation seasonal influenza virus vaccines need a neuraminidase component
This commentary highlights the potential need to incorporate neuraminidase components into future influenza vaccines
Interim data on flu vaccines estimate overall moderate protection in Europe and China
Estimates of current mid-season flu vaccine effectiveness (VE) in Europe and China range from 32% to 58% overall, with greater protection against influenza B than A, according to three studies published in Eurosurveillance.
XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies
The evolution of the antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is impacted by the nature and number of antigenic exposures.
Recommendations announced for influenza vaccine composition for the 2025–2026 northern hemisphere influenza season
WHO announced them at the meeting on the composition of Influenza Virus Vaccines. These gatherings are held twice a year, bringing together an advisory group of experts from WHO Collaborating Centres and WHO Essential Regulatory Laboratories.
COVID-19 vaccine during pregnancy reduces risks to mother and baby
Pregnant women with COVID-19 are more likely to develop severe COVID-19 and related ill health than non-pregnant women of similar age.